Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PODD

Insulet Corporation

Feb 13 • 04:00PM ET

242.74

+1.92 0.80 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM JNJ ABT MDT EW SYK TNDM BSX BAX LIVN

| Held by: VTI VOO VB VO IVV SPY VUG RSP VBK XLV

Index	S&P 500	P/E	70.43	EPS (ttm)	3.45	Insider Own	0.41%	Shs Outstand	70.35M	Perf Week	0.33%
Market Cap	17.08B	Forward P/E	38.99	EPS next Y	6.23	Insider Trans	-2.25%	Shs Float	70.06M	Perf Month	-14.19%
Enterprise Value	17.35B	PEG	1.12	EPS next Q	1.46	Inst Own	101.84%	Short Float	2.76%	Perf Quarter	-27.94%
Income	246.20M	P/S	6.77	EPS this Y	50.72%	Inst Trans	-0.46%	Short Ratio	2.32	Perf Half Y	-23.13%
Sales	2.52B	P/B	12.34	EPS next Y	27.48%	ROA	8.13%	Short Interest	1.93M	Perf YTD	-14.60%
Book/sh	19.68	P/C	22.55	EPS next 5Y	34.68%	ROE	19.68%	52W High	354.88 -31.60%	Perf Year	-13.96%
Cash/sh	10.77	P/FCF	40.31	EPS past 3/5Y	186.88% 98.82%	ROIC	10.62%	52W Low	230.05 5.52%	Perf 3Y	-18.71%
Dividend Est.	-	EV/EBITDA	32.08	Sales past 3/5Y	23.54% 22.92%	Gross Margin	72.11%	Volatility	3.66% 3.36%	Perf 5Y	-16.23%
Dividend TTM	-	EV/Sales	6.88	EPS Y/Y TTM	-41.72%	Oper. Margin	17.32%	ATR (14)	8.78	Perf 10Y	872.13%
Dividend Ex-Date	-	Quick Ratio	2.14	Sales Y/Y TTM	27.12%	Profit Margin	9.76%	RSI (14)	30.91	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	2.83	EPS Q/Q	14.88%	SMA20	-6.47%	Beta	1.43	Target Price	373.28
Payout	0.00%	Debt/Eq	0.75	Sales Q/Q	29.86%	SMA50	-12.85%	Rel Volume	0.93	Prev Close	240.82
Employees	3900	LT Debt/Eq	0.68	Earnings	Feb 18 BMO	SMA200	-20.33%	Avg Volume	834.06K	Price	242.74
IPO	May 15, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.75% 4.11%	Trades		Volume	776,046	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	TD Cowen	Hold	$294
Jan-12-26	Downgrade	Barclays	Overweight → Equal Weight	$274
Dec-16-25	Initiated	Evercore ISI	Outperform	$370
Nov-19-25	Upgrade	UBS	Neutral → Buy	$400
Oct-21-25	Resumed	Stifel	Buy	$370
Sep-08-25	Resumed	Oppenheimer	Outperform	$365
Jun-16-25	Initiated	Truist	Buy	$365
May-30-25	Initiated	Goldman	Buy	$380
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$350
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform	$340
Nov-06-24	Initiated	Bernstein	Outperform	$300
May-30-24	Initiated	Redburn Atlantic	Buy	$235
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$200
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform	$180 → $238
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$185 → $234
Oct-02-23	Upgrade	Jefferies	Hold → Buy	$260 → $240
Aug-21-23	Upgrade	Citigroup	Neutral → Buy	$273 → $265
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral	$320 → $219
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$343

Show Previous Ratings

Today 06:53AM	Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update (Insider Monkey)
Feb-13-26 04:36PM	Analyst Report: DexCom, Inc. (Morningstar Research)
11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 09:15AM	Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-11-26 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:40AM	Loading…
Feb-10-26 07:40AM	Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-05-26 07:00AM	Insulet Launches Omnipod 5 and Omnipod Discover in the Middle East to Transform Diabetes Care (Business Wire)
Feb-02-26 07:50PM	Insulet Corporation (PODD): A Bull Case Theory (Insider Monkey)
Jan-30-26 02:31PM	Reasons Why Hedge Funds Favor Insulet Corp (PODD) (Insider Monkey)
Jan-29-26 09:08PM	Analyst Report: Insulet Corporation (Morningstar Research)
Jan-27-26 09:37AM	Target upgraded, Stryker downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Affirm Holdings, Alcoa, Block, Coinbase Global,CoreWeave, Datadog, Intuitive Surgical, and More (24/7 Wall St.)
Jan-26-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
Jan-23-26 07:30PM	Analyst Report: DexCom, Inc. (Morningstar Research)
Jan-22-26 08:59PM	Analyst Report: DexCom, Inc. (Morningstar Research)
08:24AM	Loading…
08:24AM	What You Need To Know Ahead of Insulets Earnings Release (Barchart)
Jan-21-26 05:00AM	BVI appoints Jim Hollingshead as CEO (MedTech Dive)
Jan-20-26 07:20PM	Is Insulet (PODD) the Future of Diabetes Management? (Motley Fool)
Jan-15-26 05:26AM	JPM26: Insulet presents optimistic growth plan heading into 2026 (Medical Device Network)
Jan-14-26 12:53PM	Bernstein Reduces Firm's PT on Insulet (PODD) Stock (Insider Monkey)
Jan-12-26 09:49AM	Netflix initiated, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-09-26 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
06:00AM	Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 (Business Wire)
Jan-08-26 09:33AM	What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? (Insider Monkey)
Jan-06-26 07:00AM	Insulet Redefines Diabetes at CES with "Liveable Technology" - A New Frontier in Human-Centered Connected Health (Business Wire)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
07:34AM	Is it the Right Time to Add Insulet Stock to Your Portfolio? (Zacks)
Dec-31-25 04:54AM	Best Growth Stocks to Buy for December 31st (Zacks)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:33AM	Reasons to Add Cooper Companies Stock to Your Portfolio Now (Zacks)
07:32AM	Loading…
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-29-25 08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-26-25 12:45PM	3 Reasons Growth Investors Will Love Insulet (PODD) (Zacks)
07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	Reasons to Retain Baxter International Stock in Your Portfolio Now (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
08:42AM	Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 (Insider Monkey)
07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
01:50AM	Medtronics diabetes spinoff MiniMed files for IPO (MedTech Dive)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 10:32AM	Is Insulet Stock Underperforming the Nasdaq? (Barchart)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
07:00AM	Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 07:54AM	4 Medical Device Stocks to Buy for Healthy Returns in 2026 (Zacks)
07:00AM	Insulet Expands Omnipod U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future (Business Wire)
Dec-11-25 08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 12:45PM	Here is Why Growth Investors Should Buy Insulet (PODD) Now (Zacks)
Dec-08-25 10:34PM	Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers (StockStory)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-04-25 09:45AM	Here's Why Insulet (PODD) is a Strong Growth Stock (Zacks)
08:34AM	Here's Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
07:00AM	Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience (Business Wire)
Dec-01-25 11:34PM	2 Growth Stocks with Explosive Upside and 1 We Find Risky (StockStory) -5.00%
Nov-24-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
05:47AM	Insulet unveils plans for new diabetes devices (MedTech Dive)
05:15AM	Zacks.com featured highlights include Insulet, Sandisk and O-I Glass (Zacks)
Nov-21-25 06:36PM	Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know (StockStory) +5.84%
Nov-20-25 12:30PM	Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day (Business Wire) -9.66%
07:56AM	Insulet Stock: Is Wall Street Bullish or Bearish? (Barchart)
07:03AM	3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns (Zacks)
Nov-19-25 01:45PM	Medtronic Stock Sees RS Rating Pumps Higher (Investor's Business Daily)
09:44AM	DoorDash, Baidu upgraded: Wall Street's top analyst calls (The Fly)
Nov-18-25 11:03PM	3 Reasons We Love Insulet (PODD) (StockStory)
09:45AM	Why Insulet (PODD) is a Top Growth Stock for the Long-Term (Zacks)
09:31AM	Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs (Zacks)
04:01AM	Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion (Zacks)
Nov-17-25 10:23AM	Do Options Traders Know Something About Insulet Stock We Don't? (Zacks)
09:20AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks)
Nov-13-25 12:20PM	Why Insulet (PODD) Might be Well Poised for a Surge (Zacks)
12:06PM	The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout (Investor's Business Daily)
10:00AM	Best Momentum Stocks to Buy for Nov. 13 (Zacks)
08:46AM	Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand (Zacks)
05:09AM	New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More (Zacks)
Nov-12-25 05:54AM	Zacks.com featured highlights include Insulet, Celestica and Innodata (Zacks)
Nov-11-25 11:37PM	1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds (StockStory)
03:00PM	3 Top Momentum Stocks to Buy as U.S. Shutdown Nears End (Zacks)
Nov-10-25 12:00PM	Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-07-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD) (Zacks)
09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-06-25 05:10PM	Analyst Report: Insulet Corporation (Morningstar Research)
04:06PM	Insulet Stock Goes On A Wild Journey Following Its Beat-And-Raise Quarter (Investor's Business Daily)
11:42AM	Insulet Sheds Early Gains, Sinking Despite Its Broad Omnipod Beat (Investor's Business Daily)
09:30AM	Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:43AM	Insulet Rises As Broad Omnipod Growth Stokes Beat-And-Raise Quarter (Investor's Business Daily)
07:40AM	Insulet (PODD) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:45AM	Insulet's (NASDAQ:PODD) Q3: Strong Sales (StockStory)
06:35AM	Insulet: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Insulet Reports Third Quarter 2025 Results (Business Wire)
Nov-04-25 10:20PM	Earnings To Watch: Insulet (PODD) Reports Q3 Results Tomorrow (StockStory)
02:09PM	Final Trades: Insulet Corp, Uber and Apollo Global (CNBC TV)
09:15AM	Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frederick Wayne A.I.	Director	Dec 15 '25	Sale	293.09	1,851	542,510	2,158	Dec 16 04:04 PM
Frederick Wayne A.I.	Director	Dec 15 '25	Proposed Sale	293.09	1,851	542,500		Dec 15 03:03 PM
STONESIFER TIMOTHY C.	Director	Dec 05 '25	Buy	311.73	962	299,884	4,591	Dec 08 04:02 PM
Manea Dan	Former Officer	Nov 26 '25	Proposed Sale	326.64	4,475	1,461,716		Nov 26 04:31 PM
Manea Dan	Former Officer	Nov 24 '25	Proposed Sale	340.95	2,306	786,228		Nov 24 04:06 PM
Manea Dan	Former Officer	Sep 16 '25	Proposed Sale	337.73	1,347	454,920		Sep 16 01:21 PM
Singh Prem	SVP, Global Operations	Sep 08 '25	Sale	347.49	687	238,726	3,456	Sep 09 04:19 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Option Exercise	241.10	797	192,160	4,687	Sep 09 04:16 PM
Cousin Laetitia	SVP, Reg, Quality & Compliance	Sep 08 '25	Sale	348.81	797	278,002	3,890	Sep 09 04:16 PM
Cousin Laetitia	Officer	Sep 08 '25	Proposed Sale	348.81	797	278,000		Sep 08 02:07 PM
Singh Prem	Officer	Sep 08 '25	Proposed Sale	347.48	687	238,718		Sep 08 01:31 PM
Benjamin Eric	EVP, CPXO	Aug 21 '25	Sale	332.23	4,263	1,416,296	16,736	Aug 22 04:16 PM
Benjamin Eric	Officer	Aug 21 '25	Proposed Sale	332.23	4,263	1,416,296		Aug 21 10:21 AM
Singh Prem	SVP, Global Operations	Aug 07 '25	Option Exercise	271.28	1,343	364,325	5,486	Aug 08 04:03 PM
Singh Prem	SVP, Global Operations	Aug 07 '25	Sale	320.00	1,343	429,760	4,143	Aug 08 04:03 PM
Singh Prem	Officer	Aug 07 '25	Proposed Sale	320.00	1,343	429,760		Aug 07 11:35 AM
Singh Prem	SVP, Global Operations	Jun 13 '25	Option Exercise	166.62	1,257	209,441	6,470	Jun 16 04:18 PM
Singh Prem	SVP, Global Operations	Jun 13 '25	Sale	300.05	2,327	698,216	4,143	Jun 16 04:18 PM
Manea Dan	SVP, Chief HR Officer	Jun 13 '25	Sale	300.05	1,300	390,065	9,090	Jun 16 04:16 PM
Singh Prem	Officer	Jun 13 '25	Proposed Sale	300.05	2,327	698,216		Jun 13 10:15 AM
Manea Dan	Officer	Jun 13 '25	Proposed Sale	300.05	1,300	390,065		Jun 13 09:45 AM
BORIO LUCIANA	Director	Jun 09 '25	Sale	305.73	481	147,056	3,087	Jun 10 04:17 PM
BORIO LUCIANA	Director	Jun 09 '25	Proposed Sale	305.72	481	147,054		Jun 09 01:08 PM
Hollingshead James	Former Officer	May 16 '25	Proposed Sale	323.10	15,605	5,041,964		May 16 04:40 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Option Exercise	95.43	5,278	503,680	28,458	May 15 04:25 PM
Kapples John W.	SVP and General Counsel	May 14 '25	Sale	318.47	5,278	1,680,885	23,180	May 15 04:25 PM
Hopfield Jessica	Director	May 13 '25	Option Exercise	28.87	5,235	151,134	32,152	May 14 04:15 PM
Hopfield Jessica	Director	May 13 '25	Sale	317.54	5,235	1,662,322	26,917	May 14 04:15 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Option Exercise	92.11	3,001	276,422	23,907	May 14 04:08 PM
Benjamin Eric	EVP, CPXO	May 13 '25	Sale	320.00	3,001	960,320	20,906	May 14 04:08 PM
Kapples John W.	Officer	May 14 '25	Proposed Sale	318.47	5,278	1,680,901		May 14 12:32 PM
Field Mark N	Former Officer	May 13 '25	Proposed Sale	321.31	2,457	789,459		May 13 01:44 PM
Benjamin Eric	Officer	May 13 '25	Proposed Sale	320.00	3,001	960,320		May 13 12:51 PM
Hopfield Jessica	Director	May 13 '25	Proposed Sale	317.54	5,235	1,662,322		May 13 10:19 AM
Frederick Wayne A.I.	Director	Mar 25 '25	Sale	275.00	1,825	501,875	3,231	Mar 26 04:22 PM
Frederick Wayne A.I.	Director	Mar 25 '25	Proposed Sale	275.00	1,825	501,875		Mar 25 10:30 AM
Benjamin Eric	EVP, CPXO	Mar 03 '25	Option Exercise	56.52	5,146	290,873	20,906	Mar 04 04:09 PM

Open in Screener

NVCR

NovoCure Ltd

Feb 13 • 04:00PM ET

10.99

-1.54 -12.29 %

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI IWM VB VBK VXF IWO IBB VTWO SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	10.00%	Shs Outstand	111.98M	Perf Week	8.38%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.73%	Shs Float	100.78M	Perf Month	-20.19%
Enterprise Value	992.60M	PEG	-	EPS next Q	-0.41	Inst Own	81.11%	Short Float	7.91%	Perf Quarter	-3.26%
Income	-177.65M	P/S	1.92	EPS this Y	10.17%	Inst Trans	-4.71%	Short Ratio	4.45	Perf Half Y	-5.18%
Sales	642.27M	P/B	3.61	EPS next Y	-13.94%	ROA	-13.75%	Short Interest	7.97M	Perf YTD	-15.00%
Book/sh	3.05	P/C	1.19	EPS next 5Y	7.48%	ROE	-50.60%	52W High	22.95 -52.11%	Perf Year	-49.38%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-40.48% -83.87%	ROIC	-30.70%	52W Low	9.82 11.91%	Perf 3Y	-87.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.19% 11.49%	Gross Margin	75.52%	Volatility	11.32% 6.67%	Perf 5Y	-94.21%
Dividend TTM	-	EV/Sales	1.55	EPS Y/Y TTM	-15.64%	Oper. Margin	-27.37%	ATR (14)	1.00	Perf 10Y	-9.25%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	11.17%	Profit Margin	-27.66%	RSI (14)	42.24	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-17.92%	SMA20	-9.12%	Beta	0.72	Target Price	25.21
Payout	-	Debt/Eq	2.34	Sales Q/Q	7.81%	SMA50	-14.06%	Rel Volume	1.99	Prev Close	12.53
Employees	1488	LT Debt/Eq	0.70	Earnings	Feb 26 BMO	SMA200	-21.52%	Avg Volume	1.79M	Price	10.99
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.37% 5.20%	Trades		Volume	3,568,545	Change	-12.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Loading…
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
08:10AM	Loading…
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
07:00AM	Loading…
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM

PODD

Insulet Corporation

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience